Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody
Autor: | Shigenori Kadowaki, Hiroko Hasegawa, Seiichiro Mitani, Masashi Ando, Yasushi Yatabe, Hiroya Taniguchi, Toshiki Masuishi, Kei Muro, Azusa Komori, Takashi Ura, Yukiya Narita |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research Organoplatinum Compounds genetic structures Colorectal cancer medicine.medical_treatment Leucovorin Cetuximab 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols integumentary system biology Panitumumab Antibodies Monoclonal General Medicine Middle Aged Bevacizumab ErbB Receptors Treatment Outcome 030220 oncology & carcinogenesis Female Fluorouracil Antibody Colorectal Neoplasms medicine.drug Adult medicine.medical_specialty Disease-Free Survival 03 medical and health sciences Growth factor receptor Internal medicine medicine Humans Aged Retrospective Studies Chemotherapy business.industry Retrospective cohort study medicine.disease eye diseases Clinical trial 030104 developmental biology biology.protein Camptothecin sense organs business |
Zdroj: | Oncology. 92:205-212 |
ISSN: | 1423-0232 0030-2414 |
Popis: | Objective: Anti-epidermal growth factor receptor (EGFR) antibodies and bevacizumab are commonly used, sequentially, as palliative chemotherapies for patients with metastatic colorectal cancer. However, little is known about the efficacy of second-line treatments containing bevacizumab after first-line treatment with an anti-EGFR antibody. Methods: We retrospectively reviewed 128 patients who received second-line bevacizumab-containing chemotherapy and evaluated the effect of prior use of anti-EGFR antibody on the efficacy of the second-line treatment. Results: As first-line treatments, 35 of these patients received only cytotoxic chemotherapy (cohort A), 58 received bevacizumab-containing chemotherapy (cohort B), and 35 received anti-EGFR-containing chemotherapy (cohort C). The median progression-free survival (PFS) with the second-line bevacizumab-containing therapy was 8.3 months in cohort C, 6.9 months in cohort A (hazard ratio [HR], 1.43; 95% confidence interval [CI], 0.83-2.51), and 5.6 months in cohort B (HR, 1.95; 95% CI, 1.18-3.22). Multivariate analysis showed that PFS in cohort C was the same as that in cohort A, but better than that in cohort B. The overall response rate in cohort C (25.7%) was also similar to that in cohort A (20.0%), but better than that in cohort B (10.3%). Conclusions: Prior use of anti-EGFR antibody did not adversely affect the efficacy of subsequent bevacizumab-containing chemotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |